ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million
WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the “Company”), a company specializing in molecular diagnostic solutions, healthcare software and services supporting clinical research, s raising its revenue guidance for the financial year ending 31 December 2026. Based on the commercial, operational and accounting information available as of the date of this press release, the Company now expects revenue to be between €13.5